These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

832 related articles for article (PubMed ID: 21555689)

  • 1. Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031.
    Ellis MJ; Suman VJ; Hoog J; Lin L; Snider J; Prat A; Parker JS; Luo J; DeSchryver K; Allred DC; Esserman LJ; Unzeitig GW; Margenthaler J; Babiera GV; Marcom PK; Guenther JM; Watson MA; Leitch M; Hunt K; Olson JA
    J Clin Oncol; 2011 Jun; 29(17):2342-9. PubMed ID: 21555689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ki67 Proliferation Index as a Tool for Chemotherapy Decisions During and After Neoadjuvant Aromatase Inhibitor Treatment of Breast Cancer: Results From the American College of Surgeons Oncology Group Z1031 Trial (Alliance).
    Ellis MJ; Suman VJ; Hoog J; Goncalves R; Sanati S; Creighton CJ; DeSchryver K; Crouch E; Brink A; Watson M; Luo J; Tao Y; Barnes M; Dowsett M; Budd GT; Winer E; Silverman P; Esserman L; Carey L; Ma CX; Unzeitig G; Pluard T; Whitworth P; Babiera G; Guenther JM; Dayao Z; Ota D; Leitch M; Olson JA; Allred DC; Hunt K
    J Clin Oncol; 2017 Apr; 35(10):1061-1069. PubMed ID: 28045625
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Endocrine-Sensitive Disease Rate in Postmenopausal Patients With Estrogen Receptor-Rich/ERBB2-Negative Breast Cancer Receiving Neoadjuvant Anastrozole, Fulvestrant, or Their Combination: A Phase 3 Randomized Clinical Trial.
    Ma CX; Suman VJ; Sanati S; Vij K; Anurag M; Leitch AM; Unzeitig GW; Hoog J; Fernandez-Martinez A; Fan C; Gibbs RA; Watson MA; Dockter TJ; Hahn O; Guenther JM; Caudle A; Crouch E; Tiersten A; Mita M; Razaq W; Hieken TJ; Wang Y; Rimawi MF; Weiss A; Winer EP; Hunt KK; Perou CM; Ellis MJ; Partridge AH; Carey LA
    JAMA Oncol; 2024 Mar; 10(3):362-371. PubMed ID: 38236590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics.
    Ellis MJ; Tao Y; Luo J; A'Hern R; Evans DB; Bhatnagar AS; Chaudri Ross HA; von Kameke A; Miller WR; Smith I; Eiermann W; Dowsett M
    J Natl Cancer Inst; 2008 Oct; 100(19):1380-8. PubMed ID: 18812550
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Local-Regional Recurrence After Neoadjuvant Endocrine Therapy: Data from ACOSOG Z1031 (Alliance), a Randomized Phase 2 Neoadjuvant Comparison Between Letrozole, Anastrozole, and Exemestane for Postmenopausal Women with Estrogen Receptor-Positive Clinical Stage 2 or 3 Breast Cancer.
    Hunt KK; Suman VJ; Wingate HF; Leitch AM; Unzeitig G; Boughey JC; Meric-Bernstam F; Ellis MJ; Olson J
    Ann Surg Oncol; 2023 Apr; 30(4):2111-2118. PubMed ID: 36653664
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Challenges in the endocrine management of breast cancer.
    Mouridsen HT; Rose C; Brodie AH; Smith IE
    Breast; 2003 Aug; 12 Suppl 2():S2-19. PubMed ID: 14659138
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Association between breast cancer subtypes and response to neoadjuvant anastrozole.
    Dunbier AK; Anderson H; Ghazoui Z; Salter J; Parker JS; Perou CM; Smith IE; Dowsett M
    Steroids; 2011 Jul; 76(8):736-40. PubMed ID: 21447351
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term outcome of neoadjuvant endocrine therapy with aromatase inhibitors in elderly women with hormone receptor-positive breast cancer.
    Grassadonia A; Di Nicola M; Grossi S; Noccioli P; Tavoletta S; Politi R; Angelucci D; Marinelli C; Zilli M; Ausili Cefaro G; Tinari N; De Tursi M; Iezzi L; Cioffi P; Iacobelli S; Natoli C; Cianchetti E
    Ann Surg Oncol; 2014 May; 21(5):1575-82. PubMed ID: 24522992
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of the efficacy of aromatase inhibitors in second-line treatment of metastatic breast cancer.
    Rose C
    Am J Clin Oncol; 2003 Aug; 26(4):S9-16. PubMed ID: 12902872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ki67 index changes, pathological response and clinical benefits in primary breast cancer patients treated with 24 weeks of aromatase inhibition.
    Toi M; Saji S; Masuda N; Kuroi K; Sato N; Takei H; Yamamoto Y; Ohno S; Yamashita H; Hisamatsu K; Aogi K; Iwata H; Takada M; Ueno T; Saji S; Chanplakorn N; Suzuki T; Sasano H
    Cancer Sci; 2011 Apr; 102(4):858-65. PubMed ID: 21231986
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hormonal therapies for early breast cancer: systematic review and economic evaluation.
    Hind D; Ward S; De Nigris E; Simpson E; Carroll C; Wyld L
    Health Technol Assess; 2007 Jul; 11(26):iii-iv, ix-xi, 1-134. PubMed ID: 17610808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial.
    Ellis MJ; Coop A; Singh B; Mauriac L; Llombert-Cussac A; Jänicke F; Miller WR; Evans DB; Dugan M; Brady C; Quebe-Fehling E; Borgs M
    J Clin Oncol; 2001 Sep; 19(18):3808-16. PubMed ID: 11559718
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-tumor effects of letrozole.
    Miller WR; Anderson TJ; Dixon JM
    Cancer Invest; 2002; 20 Suppl 2():15-21. PubMed ID: 12442345
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase 2 randomized trial of primary endocrine therapy versus chemotherapy in postmenopausal patients with estrogen receptor-positive breast cancer.
    Semiglazov VF; Semiglazov VV; Dashyan GA; Ziltsova EK; Ivanov VG; Bozhok AA; Melnikova OA; Paltuev RM; Kletzel A; Berstein LM
    Cancer; 2007 Jul; 110(2):244-54. PubMed ID: 17538978
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Superior suppression of serum estrogens during neoadjuvant breast cancer treatment with letrozole compared to exemestane.
    Bertelsen BE; Almås B; Fjermeros K; Viste K; Geisler SB; Sauer T; Selsås K; Geisler J
    Breast Cancer Res Treat; 2024 Jul; 206(2):347-358. PubMed ID: 38649619
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A decade of letrozole: FACE.
    O'Shaughnessy J
    Breast Cancer Res Treat; 2007; 105 Suppl 1(Suppl 1):67-74. PubMed ID: 17912637
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparative Efficacy and Safety of Adjuvant Letrozole Versus Anastrozole in Postmenopausal Patients With Hormone Receptor-Positive, Node-Positive Early Breast Cancer: Final Results of the Randomized Phase III Femara Versus Anastrozole Clinical Evaluation (FACE) Trial.
    Smith I; Yardley D; Burris H; De Boer R; Amadori D; McIntyre K; Ejlertsen B; Gnant M; Jonat W; Pritchard KI; Dowsett M; Hart L; Poggio S; Comarella L; Salomon H; Wamil B; O'Shaughnessy J
    J Clin Oncol; 2017 Apr; 35(10):1041-1048. PubMed ID: 28113032
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Emerging role of aromatase inhibitors in the adjuvant setting.
    Goss PE
    Am J Clin Oncol; 2003 Aug; 26(4):S27-33. PubMed ID: 12902874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exemestane versus anastrozole in postmenopausal women with early breast cancer: NCIC CTG MA.27--a randomized controlled phase III trial.
    Goss PE; Ingle JN; Pritchard KI; Ellis MJ; Sledge GW; Budd GT; Rabaglio M; Ansari RH; Johnson DB; Tozer R; D'Souza DP; Chalchal H; Spadafora S; Stearns V; Perez EA; Liedke PE; Lang I; Elliott C; Gelmon KA; Chapman JA; Shepherd LE
    J Clin Oncol; 2013 Apr; 31(11):1398-404. PubMed ID: 23358971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Are all aromatase inhibitors the same? A review of controlled clinical trials in breast cancer.
    Berry J
    Clin Ther; 2005 Nov; 27(11):1671-84. PubMed ID: 16368441
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 42.